Open AccessThe Positive Nuclear Staining Observed with Monoclonal Antibody against PRAD1/Cyclin D1 Correlates with mRNA Expression in Mantle Cell Lymphoma
Author(s) -
Kuroda Hiroyuki,
Komatsu Hirokazu,
Nakamura Shigeo,
Niitsu Yoshiro,
Takahashi Toshitada,
Ueda Ryuzo,
Seto Masao
Publication year - 1995
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1995.tb03102.x
Subject(s) - biology , cyclin d1 , microbiology and biotechnology , immunostaining , staining , monoclonal antibody , lymphoma , antibody , cyclin , cell nucleus , mantle zone , messenger rna , western blot , northern blot , immunohistochemistry , cell cycle , cytoplasm , cell , gene , b cell , immunology , biochemistry , germinal center , genetics
Recently, we produced a monoclonal antibody, 5D4, against the PRAD1/cyclin D1 product and suggested positive nuclear staining to be associated with mantle cell lymphoma (MCL). Now we have further characterized the specificity of this antibody and studied the relation of immunohistochemical detection to PRAD1/cyclin D1 mRNA expression and DNA rearrangement. Immunofluorescence and immunoblotting studies demonstrated the 5D4 antibody to be crossreactive with cyclin D2, but not cyclin D3. On immunostaining, 15 of 19 MCL cases (79%) presented the nuclear staining pattern and PRAD1/cyclin D1 mRNA expression was detected by Northern blot analysis in 12 of 15 MCL cases studied (80%); all cases with the mRNA expression showed the nuclear staining pattern. Southern blot analysis with 11q13 BCL‐1 probes detected DNA rearrangements in 8 of 19 MCL cases (42%), all 8 exhibiting PRAD1/cyclin D1 mRNA expression. In 21 lymphoma cases of types other than MCL, neither the mRNA expression nor the nuclear staining were observed, although cytoplasmic staining was often apparent. These results indicated that positive nuclear staining of lymphoma cells by 5D4 antibody reflects PRAD1/cyclin D1 mRNA expression, and showed that this monoclonal antibody has diagnostic value for differentiating MCL from other types of lymphomas.